公司概述
Mainz Biomed N.V. is a specialized enterprise focused on the development and commercialization of in-vitro diagnostic (IVD) tests designed for the early detection of cancer within the United States and European markets. The company operates within the healthcare sector, specifically targeting the diagnostics and research industry, which implies a reliance on advanced molecular biology and genetic testing technologies to identify pathological conditions before clinical symptoms manifest. Mainz Biomed N.V. is a micro-cap entity with a market capitalization of $5.95M, generating trailing twelve-month revenue of $1.07M, and it currently reports an employee count listed as N/A. These valuation figures indicate that the company is in an early-stage growth phase where revenue generation is prioritized over profitability, typical for biotechnology firms investing heavily in research and development to bring proprietary tests like ColoAlert and PancAlert to market.
财务健康
The company reported a trailing twelve-month revenue of $1.07M alongside a net income of $-16,210,718, a significant disparity that reveals an extremely aggressive cost structure where operating expenses vastly exceed gross profit generation. EBITDA stands at $-12,349,595, further confirming that the business model is currently cash-burn heavy rather than profit-generative. Free cash flow is reported at $-9,546,315, indicating that the company is consuming its liquid assets to fund operations and R&D, which limits immediate financial flexibility but is common for development-stage diagnostics companies. The gross margin stands at 81.1%, suggesting high efficiency in producing the stool-based screening tests, whereas the operating margin is a severe -621.8% and profit margin is 0.0%, highlighting that administrative and R&D costs are consuming the entire gross profit. On the balance sheet, the company holds $889,091 in cash against $2.57M in debt, resulting in a debt-to-equity ratio of 400.80, which characterizes a highly leveraged position relative to its equity base. The current ratio of 0.50 indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity constraints that could require capital raises or asset liquidation. Return on Equity is -484.8% and Return on Assets is -87.3%, metrics that reveal that management has not yet generated returns on invested capital, reflecting the high risk and long development timelines inherent in the cancer diagnostic sector.
估值评估
Trailing P/E and forward P/E are both listed as N/A due to the company's negative earnings, which implies that traditional earnings-based valuation multiples are currently inapplicable and that investors must rely on alternative metrics to assess value. The price-to-book ratio is 0.77, indicating that the market is valuing the company at a discount to its net asset book value, a common occurrence for speculative biotech firms with limited operating history. Price-to-sales stands at 5.55 and EV/EBITDA is -0.50; these alternative metrics suggest that the market is pricing in future growth potential rather than current cash flows, as the negative EV/EBITDA reflects the significant debt burden and lack of current earnings. The 52-week high is $4.43 and the 52-week low is $0.40, placing the current trading environment within a wide volatility range that reflects the speculative nature of the stock. The beta value is listed as N/A, meaning that historical volatility data is insufficient to quantify the stock's sensitivity to broader market movements compared to the broader market.
Growth & Income
Revenue growth year-over-year is 86.9%, demonstrating rapid expansion in sales volume, while earnings growth is N/A because the company has not yet achieved positive net income, meaning earnings are not growing in a traditional sense but rather moving from deeper losses toward breakeven. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available cash flow is being reinvested into research and development rather than distributed to shareholders. The absence of a dividend payout aligns with the company's lifecycle stage, where capital retention is essential to sustain the high burn rate required for product development and regulatory approval. Overall, the growth and income profile is characterized by high revenue expansion and zero income distribution, reflecting a strategy focused entirely on scaling the IVD test portfolio rather than providing current yield.